Clinical Trials Logo

Venous Thromboembolism clinical trials

View clinical trials related to Venous Thromboembolism.

Filter by:

NCT ID: NCT00952380 Completed - Clinical trials for Venous Thromboembolism

Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients

Start date: August 2009
Phase: Phase 2
Study type: Interventional

Three month treatment of acute VTE with Fragmin in pediatric cancer patients

NCT ID: NCT00942435 Completed - Clinical trials for Venous Thromboembolism

A Study to Assess the Effect of YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery

Start date: June 2009
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the efficacy and safety of the oral dose of YM150 for prevention of venous thromboembolism (VTE) in patients undergoing major abdominal surgery.

NCT ID: NCT00937911 Completed - Clinical trials for Venous Thromboembolism

Prevention of Venous Thromboembolism in Subjects Undergoing Hip Fracture Surgery or Surgery in the Lower Extremities

Start date: June 2009
Phase: Phase 3
Study type: Interventional

The study objective is to evaluate the efficacy and safety of oral YM150 for prevention of venous thromboembolism in subjects undergoing hip fracture surgery or surgery in the lower extremities.

NCT ID: NCT00937820 Completed - Clinical trials for Venous Thromboembolism

Prevention of Recurrence of Venous Thromboembolism in Patients With a History of Venous Thromboembolism

Start date: June 2009
Phase: Phase 3
Study type: Interventional

The study objective is to evaluate the efficacy and safety of oral YM150 for 52 weeks in patients with a history of venous thromboembolism.

NCT ID: NCT00917254 Completed - Clinical trials for Venous Thromboembolism

Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery

Start date: May 2009
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to examine the superiority of YM150 to the placebo and to evaluate the dose-dependent response of YM150 in patients undergoing elective total knee replacement surgery.

NCT ID: NCT00913120 Completed - Clinical trials for Venous Thromboembolism

Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery

Start date: May 2009
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to examine the superiority of YM150 to the placebo and to evaluate the dose-dependent response of YM150 in patients undergoing elective total hip replacement surgery.

NCT ID: NCT00902928 Completed - Clinical trials for Venous Thromboembolism

A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery

ONYX-3
Start date: April 2009
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of various doses of YM150 (the experimental drug) compared to enoxaparin in the prevention of venous thromboembolism in patients that are undergoing elective hip replacement surgery.

NCT ID: NCT00894283 Completed - Pulmonary Embolism Clinical Trials

Comparing Enoxaparin to Fondaparinux to Prevent Venous Thromboembolism (VTE) in Bariatric Surgical Patients

Start date: June 2009
Phase: Early Phase 1
Study type: Interventional

This pilot study is designed to determine the feasibility of conducting a randomized clinical trial comparing fondaparinux sodium (Arixtra) once daily with enoxaparin (Lovenox®) twice daily with respect to preventing deep vein thrombosis (DVT) and pulmonary embolism (PE) after bariatric surgery in obese patients.

NCT ID: NCT00878826 Completed - Venous Thrombosis Clinical Trials

Prophylactic Enoxaparin Dosing for Prevention of Venous Thromboembolism in Pregnancy.

Start date: May 2009
Phase: Phase 2/Phase 3
Study type: Interventional

Enoxaparin is a type of low molecular weight heparin (LMWH), or anticoagulant, used to prevent and treat blood clots. Formation of blood clots, or venous thromboemboli (VTE) in pregnancy can have dangerous and even life-threatening effects on the mother and fetus. Enoxaparin is the preferred medicine to prevent clotting in pregnant patients who are at risk for VTE, because it has been studied to be safe and effective in pregnancy without any harms to the fetus. Although this medication is routinely used and is recommended by several prominent medical groups, the optimal dosing for prevention of VTE is still unclear. The range of standardly prescribed dosing regimens of Enoxaparin includes 40mg daily and 1mg/kg daily, but these two dosing strategies have never been compared in a head to head fashion.

NCT ID: NCT00853463 Completed - Pulmonary Embolism Clinical Trials

Discharge ALERT: Quality Improvement Initiative

Discharge
Start date: April 2009
Phase: N/A
Study type: Interventional

Brigham and Women's Hospital will coordinate a Quality Improvement Initiative at other hospitals that focuses on whether physician notification prior to discharge of high risk VTE patients will reduce the incidence of VTE after hospital discharge.